



Sustanon® '250'

Injection

(Testosterone Propionate)
(Testosterone Phenylpropionate)
(Testosterone Isocaproate)
(Testosterone Decanoate)

Composition

Each ml of the oily solution contains:

testosterone propionate (Eur. P.).....	30 mg
testosterone phenylpropionate (B.P.).....	60 mg
testosterone isocaproate (B.P.).....	60 mg
testosterone decanoate (B.P.).....	100 mg

Characteristics

Sustanon '250' is an androgenic preparation for intramuscular administration containing four different esters of the natural hormone testosterone. Testosterone propionate has a rapid onset and a short duration of action. Testosterone phenylpropionate and isocaproate have a less rapid onset and a long duration of action. By combining these testosterone esters, the action of **Sustanon '250'** starts shortly after injection and is maintained for about three weeks.

Sustanon '250' is generally well tolerated and has no adverse effect on the liver.

Indications

Testosterone replacement therapy in male hypogonadal disorders, for example:

- after castration
- eunuchoidism
- hypopituitarism
- endocrine impotence
- male climacteric symptoms such as decreased libido and decreased mental and physical activity
- certain types of infertility due to disorders of spermatogenesis;

Moreover, testosterone therapy may be indicated in osteoporosis due to androgen deficiency.

Dosage

In general, dosage should be adjusted according to the response of the individual patient. Usually, one injection of 1 ml per three weeks is adequate or as prescribed by the physician.

Administration

Sustanon '250' should be administered by deep intramuscular injection.

Contra-indications

- Known or suspected prostatic or mammary carcinoma.

Warnings and precautions

- If androgen associated adverse reactions occur, treatment should be interrupted and after disappearance of the symptoms, should be resumed at a lower dosage.
- Patients with latent or overt cardiac failure, renal dysfunction, hypertension, epilepsy or migraine (or a history of these conditions) should be monitored, since androgens may occasionally induce salt and fluid retention.
- Androgens should be used cautiously in prepubertal boys to avoid premature epiphyseal closure or precocious sexual development.
- Oligosperma and decreased ejaculatory volume.
- A decrease in protein-bound iodine (PBI) may occur, but this has no clinical significance.

Adverse reactions

The following adverse reactions have been associated with androgen therapy:

- Priapism and other signs of excessive sexual stimulation.
- In prepubertal boys, precocious sexual development, an increased frequency of erections, phallic enlargement and premature epiphyseal closure.
- Water and salt retention.
- Oligosperma and decreased ejaculatory volume.

Instructions

To be sold on the prescription of a registered medical practitioner only.

Store at 8-30°C. Protect from light.

Keep out of the reach of children.

Presentation

Box of 1 x 1 ml ampoule

M.L. No.: 000024

Manufactured by:

Pharmatec

Pakistan (Pvt) Ltd.

D-86/A S.I.T.E.,

Karachi.

For:

OBS Pakistan (Pvt) Ltd.

C-14, S.I.T.E., Karachi-75700

Under Licence from

N.V Organon Oss. The Netherlands.

Mfg. Org. Spec.

LF-SUS-01/PHT/09